Literature DB >> 19910434

18F-FDG PET as a routine posttreatment surveillance tool in oral and oropharyngeal squamous cell carcinoma: a prospective study.

Christiaan A Krabbe1, Jan Pruim, Pieter U Dijkstra, Hans Balink, Bernard F van der Laan, Jan G de Visscher, Jan L Roodenburg.   

Abstract

UNLABELLED: The purpose of this study was to evaluate the role and timing of serial (18)F-FDG PET scans as routine surveillance for detecting early locoregional recurrence, distant metastases, and second primary tumors in patients treated for advanced squamous cell carcinoma (SCC) in the oral cavity or oropharynx during the first year after completion of their curative treatment.
METHODS: Forty-eight consecutive patients with SCC in the oral cavity or oropharynx were included after completing their initial therapy with curative intent. Prospective follow-up of the participants was 2-fold: regular follow-up (history and physical examination) and serial (18)F-FDG PET scans. Patients underwent standard follow-up and (18)F-FDG PET at 3, 6, 9, and 12 mo after initial treatment. Findings were validated by histopathology or 18 mo of clinical follow-up and imaging after initial treatment.
RESULTS: Incidence of recurrences and second primary tumors was 27% and 10%, respectively. (18)F-FDG PET was significantly (P = 0.035) more often in agreement with the gold standard than was regular follow-up. (18)F-FDG PET showed a sensitivity, specificity, positive predictive value, and negative predictive value of 100%, 43%, 51%, and 100%, respectively. For regular follow-up, these values were 0%, 60%, 0%, and 50%, respectively. (18)F-FDG PET accounted for a change in diagnostics or treatment in 63% of the patients and regular follow-up in 25% of the patients. Sensitivity and specificity of (18)F-FDG PET were both irrespective of timing of (18)F-FDG PET. For the 3- and 6-mo posttherapy results combined, (18)F-FDG PET detected malignancy in 16 of the 18 patients.
CONCLUSION: (18)F-FDG PET is a suitable routine posttreatment surveillance tool in oral and oropharyngeal SCC patients and detects malignancy before clinical suggestion by the regular follow-up arises. The best timing of a systematic (18)F-FDG PET scan is between 3 and 6 mo after treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19910434     DOI: 10.2967/jnumed.109.065300

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  29 in total

1.  Qualitative interpretation of PET scans using a Likert scale to assess neck node response to radiotherapy in head and neck cancer.

Authors:  Johanna Sjövall; Ulrika Bitzén; Elisabeth Kjellén; Per Nilsson; Peter Wahlberg; Eva Brun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-02       Impact factor: 9.236

Review 2.  Present and future role of FDG-PET/CT imaging in the management of head and neck carcinoma.

Authors:  Kazuhiro Kitajima; Yuko Suenaga; Kazuro Sugimura
Journal:  Jpn J Radiol       Date:  2015-10-27       Impact factor: 2.374

3.  Evaluation of neck node response after radiotherapy: minimizing equivocal results.

Authors:  Remco de Bree; Otto S Hoekstra
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-04       Impact factor: 9.236

Review 4.  Potential Role of PET/MRI for Imaging Metastatic Lymph Nodes in Head and Neck Cancer.

Authors:  Sungheon Gene Kim; Kent Friedman; Sohil Patel; Mari Hagiwara
Journal:  AJR Am J Roentgenol       Date:  2016-05-10       Impact factor: 3.959

5.  Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis.

Authors:  Tejpal Gupta; Zubin Master; Sadhana Kannan; Jai Prakash Agarwal; Sarbani Ghsoh-Laskar; Venkatesh Rangarajan; Vedang Murthy; Ashwini Budrukkar
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-08-19       Impact factor: 9.236

6.  FDG-PET/contrast-enhanced CT as a post-treatment tool in head and neck squamous cell carcinoma: comparison with FDG-PET/non-contrast-enhanced CT and contrast-enhanced CT.

Authors:  Yuko Suenaga; Kazuhiro Kitajima; Takeaki Ishihara; Ryohei Sasaki; Naoki Otsuki; Ken-Ichi Nibu; Tsutomu Minamikawa; Naomi Kiyota; Kazuro Sugimura
Journal:  Eur Radiol       Date:  2015-07-19       Impact factor: 5.315

7.  Prognostic value of 18F-FDG uptake by regional lymph nodes on pretreatment PET/CT in patients with resectable colorectal cancer.

Authors:  Byung Hyun Byun; Sun Mi Moon; Ui Sup Shin; Ilhan Lim; Byung Il Kim; Chang Woon Choi; Sang Moo Lim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07-03       Impact factor: 9.236

8.  Diagnostic performance of FDG PET/CT to detect subclinical HNSCC recurrence 6 months after the end of treatment.

Authors:  Philippe Robin; Ronan Abgral; Gérald Valette; Pierre-Yves Le Roux; Nathalie Keromnes; Jean Rousset; Gaël Potard; Xavier Palard; Rémi Marianowski; Pierre-Yves Salaun
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-08-29       Impact factor: 9.236

Review 9.  Functional imaging in radiation therapy planning for head and neck cancer.

Authors:  Luis A Pérez Romasanta; María José García Velloso; Antonio López Medina
Journal:  Rep Pract Oncol Radiother       Date:  2013-11-09

10.  Usefulness of esophagogastroduodenoscopy and 18F-fluorodeoxyglucose positron-emission tomography in detecting synchronous multiple primary cancers with oral cancer.

Authors:  Naomi Ishibashi-Kanno; Kenji Yamagata; Fumihiko Uchida; Shogo Hasegawa; Toru Yanagawa; Hiroki Bukawa
Journal:  Oral Maxillofac Surg       Date:  2017-08-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.